Literature DB >> 7287221

Spontaneous cytogenetic abnormalities in lymphocytes from thirteen patients with ataxia telangiectasia.

A M Taylor, J M Oxford, J A Metcalfe.   

Abstract

Ataxia telangiectasia (AT) is a human autosomal recessive disorder in which patients show a marked predisposition to malignant disease and cytogenetic abnormalities. We report here the levels of spontaneously occurring chromosome aberrations and particularly the presence of cytogenetically marked clones of cells in peripheral lymphocytes of 13 patients. There is a variation between the patients with respect to frequency of different aberration types, and clones are present in 5/13 patients. Several of these patients appear to have more than a single clone, possible clones or subclones. There is no evidence for any malignant disease in any of these patients. A description is given from one of these patients, of the most complex clone so far reported in an AT patient without malignant disease. The development of such a complex clone might be important as a step in malignant change. Similarities between this clone and one reported in an AT patient with T-cell chronic lymphocytic leukaemia are discussed.

Entities:  

Mesh:

Year:  1981        PMID: 7287221     DOI: 10.1002/ijc.2910270309

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Telomere association of chromosomes induced by aphidicolin in a normal individual.

Authors:  C Fuster; R Miró; L Barrios; J Egozcue
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

2.  Variant of ataxia-telangiectasia with low-level radiosensitivity.

Authors:  M Fiorilli; A Antonelli; G Russo; M Crescenzi; M Carbonari; P Petrinelli
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

3.  Fine mapping of the chromosome 11q22-23 region using PFGE, linkage and haplotype analysis; localization of the gene for ataxia telangiectasia to a 5cM region flanked by NCAM/DRD2 and STMY/CJ52.75, phi 2.22.

Authors:  C M McConville; C J Formstone; D Hernandez; J Thick; A M Taylor
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

4.  Tissue specificity of chromosomal rearrangements in ataxia-telangiectasia.

Authors:  T L Kojis; R R Schreck; R A Gatti; R S Sparkes
Journal:  Hum Genet       Date:  1989-11       Impact factor: 4.132

5.  Acquired chromosome rearrangements in human lymphocytes: effect of aging.

Authors:  M Prieur; W Al Achkar; A Aurias; J Couturier; A M Dutrillaux; B Dutrillaux; A Flüry-Herard; M Gerbault-Seureau; F Hoffschir; E Lamoliatte
Journal:  Hum Genet       Date:  1988-06       Impact factor: 4.132

6.  Molecular characterization of different ataxia telangiectasia T-cell clones. I. A common breakpoint at the 14q11.2 band splits the T-cell receptor alpha-chain gene.

Authors:  M H Stern; F R Zhang; C Griscelli; G Thomas; A Aurias
Journal:  Hum Genet       Date:  1988-01       Impact factor: 4.132

7.  In vivo chromosomal instability in ataxia-telangiectasia homozygotes and heterozygotes.

Authors:  M P Rosin; H D Ochs
Journal:  Hum Genet       Date:  1986-12       Impact factor: 4.132

8.  The breakpoint of an inversion of chromosome 14 in a T-cell leukemia: sequences downstream of the immunoglobulin heavy chain locus are implicated in tumorigenesis.

Authors:  R Baer; A Heppell; A M Taylor; P H Rabbitts; B Boullier; T H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  Ataxia-ocular motor apraxia syndrome: an investigation of cellular radiosensitivity of patients and their families.

Authors:  M A Hannan; D Sigut; M Waghray; G G Gascon
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

10.  Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder.

Authors:  Regina Waltes; Reinhard Kalb; Magtouf Gatei; Amanda W Kijas; Markus Stumm; Alexandra Sobeck; Britta Wieland; Raymonda Varon; Yaniv Lerenthal; Martin F Lavin; Detlev Schindler; Thilo Dörk
Journal:  Am J Hum Genet       Date:  2009-04-30       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.